Closed · RFA-DE-10-001 · CFDA 93.121 · Discretionary

Oral Mucosal Vaccination against HIV Infection (R01)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
December 2, 2009
Close date
-
Expected awards

The verdict

Oral Mucosal Vaccination against HIV Infection (R01) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

Varies
award range
Closed
application status
93.121
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Oral Mucosal Vaccination against HIV Infection is closed (last close December 2, 2009). The parent program page for CFDA 93.121 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed December 2, 2009

Posted Jul 7 Closes Dec 2

Est. Total Funding

$2,000,000

Instrument

Grant

Description

Purpose. This FOA issued by the NIDCR, NIH, solicits R01 applications that focus on harnessing oral mucosal and innate immunity to develop prophylactic HIV vaccines delivered through the oral mucosa. Specifically, the NIDCR is seeking applications that will address studies on the: 1) mechanisms linking oral mucosal and innate immunity with systemic adaptive immunity; 2) development of HIV vaccine antigens in oral expression vectors that are stable in the oral cavity and have the ability to trigger anti-HIV protective immunity; 3) mechanisms of HIV infection of target cells in the oral cavity (e.g., epithelial cells and immune cells) and effects of oral dendritic (DC),and natural killer (NK) cell subset changes during disease progression or upon oral mucosal HIV vaccination; 4) DC-NK cells cross-talk in the oral cavity and relationship to systemic adaptive immunity upon oral mucosal HIV vaccination; 5) similarities and differences between DC-NK cells cross-talk in the oral mucosal site compared with other mucosal sites, and 6) characterization of soluble defense molecules produced in oral secretions upon oral mucosal HIV vaccination. This FOA welcomes applications that further develop already characterized target vaccine antigens and formulations and relevant model antigens for oral delivery, target validation and early preclinical evaluation in relevant animal models. This FOA will not support basic vaccine antigen discovery, HIV vaccine clinical trials, projects on enteric vaccines for oral delivery, projects on nasal delivery methods for oral mucosal HIV vaccines, or therapeutic vaccine research. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards. NIDCR intends to commit approximately $2 million in total costs (Direct costs plus Facilities and Administrative costs) in fiscal year 2010 through this announcement to support approximately 4-6 awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Market-open applicant set · includes for-profit door

The eligibility set for Oral Mucosal Vaccination against HIV Infection includes a for-profit door among 10 printed types (State governments; Public / state-controlled institutions of higher education; Federally recognized tribal governments; Native American tribal organizations (other than Federally recognized tribal governments); +6 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Health (HL). Only 91 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).

Code 00
State governments
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Oral Mucosal Vaccination against HIV Infection is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.121 may publish future NOFOs under the same assistance listing. Open program
  • Oral Health Prevention and Education indexes 107 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants